MSACL 2018 US Abstract

Topic: Tissue Imaging & Analysis

IR MALDESI: from Technological Innovations to Cancer, HIV Treatment and Exposomics

David Muddiman (Presenter)
North Carolina State University

Bio: David C. Muddiman is the Jacob and Betty Belin Distinguished Professor of Chemistry and Founder and Director of the Molecular Education, Technology, and Research Innovation Center (METRIC) at North Carolina State University in Raleigh, NC. David received his B.S. in chemistry from Gannon University (Erie, PA) in 1990 and his Ph.D. in Analytical Chemistry from the University of Pittsburgh in 1995 with David M. Hercules. Dr. Muddiman has served as a member of the ASMS Board of Directors and Treasurer of US-HUPO, and he is currently the President of US HUPO. His group has presented over 500 invited lectures and presentations, 20 plenary/keynote lectures, published over 250 peer-reviewed papers, and 4 US patents. He is the recipient of the 2015 ACS Award in Chemical Instrumentation, 2010 Biemann Medal, 2009 NCSU Alumni Outstanding Research Award, and the 2004 ACS Arthur F. Findeis Award.

Authorship: David C. Muddiman (1), Mark T. Bokhart (1), Milad Nazari (1), Mans Ekeloef (1), Kenneth Garrard (1), Jeffrey G. Manni (2), Heather B. Patisaul (1), Troy G. Ghasghaei (1), James N. Petitte (1), Elias P. Rosen (3), Corbin G. Thompson (3), and Angela D. Kashuba (3)
(1)North Carolina State University, (2)JGM Associates, (3)University of North Carolina Chapel Hill

Short Abstract

This presentation will cover new technology developments including new mid IR lasers, new optical trains for improved spatial resolution, and several interesting applications of the platform technology for MSI.

Long Abstract


New ionization sources as alternatives to MALDI have been developed in the recent decade to overcome many of the inherent limitations of MALDI. In 2005, we developed MALDESI as an innovative ionization source for direct analysis and mass spectrometry imaging. However, given the approaches relies on mid IR lasers which are harder to focus, typically have lower rep-rates at the required laser fluence for effective ablation, and the lack of a core group of scientists working this area, we have spent the last 12 years developing the technology for a host of applications including mass spectrometry imaging to overcome these limitations and demonstrate the significant advantages of this approach over MALDI.


New mid-IR laser technology will be presented, new optical trains, and a host of interesting tissue imaging applications will be presented.


We have demonstrated a spatial resolution of less than 50 microns, have a new laser with a very high rep-rate where we obtain complete ablation, a number of studies where absolute quantification has been demonstrated, exposure studies to toxins in our environment, and measuring neutotransmitters in the brain. Advances in our open source software will also be presented.

Conclusions & Discussion

New technological innovations have further enabled IR-MALDESI demonstrating high spatial resolution, high sensitivity, quantification of targeted analytes, and has provided a clearer understanding of a wide variety of key questions facing human health.

References & Acknowledgements:

We gratefully acknowledge the support of NIH for funding this work (R01GM087964)

Financial Disclosure

SalaryyesCambridge Isotope Laboratories
Board Memberno

IP Royalty: no

Planning to mention or discuss specific products or technology of the company(ies) listed above: